1. Why Jiangxi Pharma Begins With One Medicine Capital

Pharmaceutical manufacturing spans a wide range. It covers traditional Chinese medicine (TCM)—decoction pieces and patent medicines—as well as modern pharma: synthetic APIs, chemical formulations and even biologics. Whether a province's pharma sits closer to the traditional or the modern end often depends on where its origin lies.

Jiangxi's origin lies in a small city called Zhangshu. Known in the trade as China's Medicine Capital, it has carried on the processing and trading of medicinal materials for over a thousand years, leaving the old saying that medicines are incomplete without Zhangshu and lose their potency without passing through it. Because of this deep TCM mother body, the base color of Jiangxi pharma leans naturally toward Chinese medicine; only above that do Nanchang, Ganzhou and others grow their own branches in patent-medicine brands, chemical drugs and injectables. Viewed as a regional sample, Jiangxi's value lies not in ranking among the nation's largest, but in showing clearly what a province rooted in traditional TCM and extending slowly into modern pharma actually looks like.

The Tianxia Gongchang Industry Research Institute reviews Jiangxi pharmaceutical manufacturing without endorsing any investment judgment. We only lay out the real shape of three lines—Zhangshu's TCM base, Nanchang's diversified layout, and Ganzhou's single-product dependence—and honestly point out the weakness of each.

2. Zhangshu: A Thousand-Year Capital Holding Up the TCM Base

To understand Jiangxi pharma, one must first grasp how much weight Zhangshu carries.

Zhangshu's TCM tradition stretches back over a thousand years; it has long been a major national hub for collecting, trading and processing medicinal materials. What it holds up is not just reputation but real capacity: Zhangshu gathers tens of thousands of technical workers engaged in processing, production and testing of medicinal materials, with local decoction-piece makers accounting for about 40% of the province and over 70% of its annual output. Around the decoction-piece line, Zhangshu links cultivation, processing, trading and finished-medicine production into a relatively complete chain, and its planting area has grown sharply from years earlier. By around 2022, Zhangshu's full-chain TCM revenue had crossed the 100-billion-yuan scale—rare at the size of a county-level city.

The base color of this line is the word "processing." Decoction pieces look basic, but the threshold lies not entirely in scale; it lies in the accumulation of authentic materials and traditional processing craft. The same herb, processed well or poorly, directly affects efficacy. Zhangshu has stood for a thousand years on this craft and trading network, not on raw volume. It is the thickest and steadiest part of Jiangxi pharma.

But the concern of the decoction-piece line is clear: pieces carry low overall added value, firms are many and scattered, and standardization and quality consistency remain hard problems. As the industry stresses full-process quality traceability and modernized processing, how an old capital upgrades its handed-down craft into mass-producible, traceable standard products is a hurdle Zhangshu cannot bypass. In recent years the locality has explicitly set its direction on quality improvement across the TCM chain, trying to let the capital's name stand on today's quality rather than on history alone.

3. Nanchang Xiaolan: From One Bottle of Shenbao to Chemical Drugs and APIs

If Zhangshu represents the root of Jiangxi pharma, Nanchang represents its trunk extending toward modern pharma. That trunk concentrates around the Xiaolan industrial park.

The first to make Nanchang's patent-medicine name was Huiren Pharmaceutical. Founded in the early 1990s and headquartered in Nanchang's Xiaolan, this patent-medicine firm built a nationally known tonic OTC brand on a single product, Shenbao; by around 2000 the annual output value of Huiren Shenbao had passed one billion yuan, pioneering a style of brand advertising for patent medicines. Huiren's lines concentrate on tonic TCM, decoction pieces and functional foods, making it the most typical brand-driven player in Jiangxi patent medicine.

But what truly pushed Nanchang's line from patent medicine toward more modern pharma was Jimin Kexin. Founded in the late 1990s and also headquartered in Nanchang, this health-industry group spans innovative drugs, chemical drugs and APIs, employs over ten thousand people, runs several modern pharmaceutical bases and has built a cross-regional and even cross-border R&D system. Its products include patent medicines and TCM injectables as well as chemical formulations and APIs, with formulations and APIs sold to more than thirty countries and regions. On successive China pharmaceutical-industry top-100 lists, Jimin Kexin sits perennially near the front—one of the few Jiangxi leaders with genuine chemical-drug and API capability climbing toward innovative drugs.

The meaning of Nanchang's line lies in a character wholly unlike Zhangshu's: Zhangshu competes on TCM processing craft and trading, while Nanchang competes on industrial depth running from patent-medicine brands all the way to chemical drugs, APIs and innovative drugs. Its scale may not surpass Zhangshu's TCM base, yet it represents the few forces in Jiangxi pharma moving toward higher added value and modern pharma. Nanchang is accordingly placed within the province's "one city, one capital, many parks" layout as the Xiaolan pharma segment, forming, together with Jinxian's medical devices, a pharma cluster around the provincial capital.

4. Ganzhou Qingfeng: An Injectable Line Held Up by a Single Product

Shifting from Nanchang in the north to the south, Jiangxi pharma's third face appears: Qingfeng Pharmaceutical in Ganzhou.

Qingfeng was once a local pharmaceutical plant; early this century it restructured and moved to Ganzhou, beginning group-scale development, and now holds production, sales and R&D arms in Ganzhou, Beijing, Hangzhou and elsewhere. It is best known for its TCM-injectable line, whose core product, Xiyanping injection, once ranked among the leaders nationally in its category, with single-product annual sales once reaching the scale of several billion yuan. In recent years Qingfeng has also moved toward innovative TCM, gaining approval for a self-developed new TCM drug and winning a national science and technology progress award. It represents another growth path in Jiangxi pharma—not spreading a broad full line, but holding up a firm on one flagship product.

The fragility of this line lies precisely in that single-product dependence. The TCM-injectable category itself sits in long-running safety controversy, with regulators steadily tightening requirements on clinical use and quality standards; Qingfeng's core product was once required to halt sales and recall over quality issues. When a firm stakes too many chips on a single category and single product, any policy or safety headwind to that category presses the whole line. Qingfeng's shift toward innovative TCM and diversification is exactly an attempt to answer this: as the injectable road narrows, can it move the eggs out of one basket through new drugs.

5. The Provincial Map and a Risk Assessment

Pulling the three lines together, Jiangxi pharmaceutical manufacturing takes a shape of "rooted in TCM, extending toward the modern": Zhangshu, with the processing and trading of a thousand-year capital, holds up the province's thickest decoction-piece base—local piece makers account for about 40% of the province and over 70% of its output, with full-chain revenue past 100 billion yuan; Nanchang's Xiaolan, with Huiren's Shenbao and Jimin Kexin's chemical drugs, APIs and innovative drugs, pushes the mix from patent medicine into the depth of modern pharma; Ganzhou's Qingfeng, with Xiyanping injection at its core, runs a single-product-driven injectable line. At the provincial level, Jiangxi organizes under "one city, one capital, many parks"—the Nanchang Xiaolan pharma, Zhangshu and Yuanzhou pharma, Jinxian medical devices and Xiajiang biopharma clusters advancing separately—with Yichun and Nanchang together holding over half the province's pharma firms, the medium-term provincial pharma-chain revenue target set at the scale of 150 billion yuan, and TCM still placed in the heaviest position.

Its risks divide just as clearly. Zhangshu's root runs deep, yet it is constrained by low decoction-piece added value, scattered small firms, and standardization and quality traceability still to be filled in; Nanchang's modern depth points the right way, but its patent-medicine leader has shown recent signs of revenue pressure and a missing second growth curve, while chemical drugs and APIs face nationwide procurement and price pressure; Ganzhou Qingfeng's single-product dependence ties its fate too tightly to one contested category. The three lines run from traditional TCM at one end to modern pharma and the regulatory frontier at the other, differing so greatly in structure that no single sentence can sum them up.

For sales teams supplying Jiangxi pharmaceutical manufacturers upstream—whether medicinal materials and decoction-piece feedstock, pharmaceutical excipients and packaging, or production and testing equipment—reaching the province's decoction-piece, patent-medicine, chemical-drug and API factory customers in bulk can run through Tianxia Gongchang to filter Jiangxi pharmaceutical manufacturing factory directories and decision-maker contacts by region and industry, turning upstream customer development from door-to-door inquiry into following the map of the medicine capital and the parks.

The Institute's assessment is this: the point of Jiangxi pharma lies not in how much output any one line can push out, but in whether it can complete the task of growing a sustainable modern-pharma trunk out of one capital's thick base—whether Zhangshu can upgrade thousand-year processing into mass-producible, traceable standardized TCM; whether Nanchang, after patent-medicine growth peaks, can add a new engine through chemical drugs, APIs and innovative drugs; and whether Ganzhou can carry a firm built on one product past the ceiling of its category. These three questions share no common solution, yet together they decide whether Jiangxi pharma can move from a present that is heavy on TCM and light on the modern toward a next stage where both root and new branch hold firm. A medicine capital gave Jiangxi its steadiest starting point; whether it can travel far from that start depends on whether it is willing to grow a few new bones beyond the old name.

Data Sources

  • Tianxia Gongchang (Jiangxi pharmaceutical manufacturing factory directory and industry data)
  • China News Service Jiangxi and China News Service: Zhangshu's full-chain TCM revenue crossing 100 billion yuan and pharma cluster development
  • Zhangshu Municipal Government, Xinhua Economic Information Daily, China Daily: Zhangshu's share of the province's decoction-piece firms and output, medicinal-material planting area, and full-chain quality improvement
  • Huiren Pharmaceutical reference entries and Huiren Group website: founding period, Xiaolan headquarters, Shenbao product and output value
  • China Pharmaceutical News, PharmCube database: Jimin Kexin founding period, Nanchang headquarters, chemical-drug, API and innovative-drug business, export countries and China pharmaceutical-industry top-100 ranking
  • Jiangxi Qingfeng Pharmaceutical reference entries and Huajing Industry Research reports: Qingfeng's restructuring and move to Ganzhou, Xiyanping injection market position and sales, the recall event, and innovative-TCM approval and national science award
  • Jiangxi and Nanchang governments, Sina Finance and Qianzhan Industry Research Institute Jiangxi pharma-chain charts: the one-city-one-capital-many-parks layout, the Yichun and Nanchang firm shares, the medium-term provincial revenue target, and the 2023 first-half pharma-manufacturing revenue change
  • Tencent News, 36Kr: revenue change of Jiangxi TCM leader Jiangzhong Pharmaceutical and its missing second growth curve